Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 10/20 | 0.47 |
| ▸ | AR | P10275 | 2/20 | 0.45 |
| ▸ | ESRRA | P11474 | 3/20 | 0.41 |
| ▸ | TTR | P02766 | 1/20 | 0.41 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.39 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14656177 | 0.93 | SLC22A12 (0.48) | SLC22A12ARESRRATTRPLA2G7 | |
| SCHEMBL14661910 | 0.93 | AR (0.50) | SLC22A12ARESRRATTRPLA2G7 | |
| SCHEMBL14661906 | 0.90 | SLC22A12 (0.48) | SLC22A12ARESRRATTR | |
| SCHEMBL14656186 | 0.89 | SLC22A12 (0.51) | SLC22A12ARESRRAPLA2G7 | |
| SCHEMBL14662061 | 0.89 | AR (0.44) | SLC22A12ARESRRATTRPLA2G7 | |
| SCHEMBL14663535 | 0.89 | TTR (0.41) | SLC22A12ARESRRATTRALDH1A1 | |
| SCHEMBL14662287 | 0.87 | AR (0.54) | ARESRRA | |
| SCHEMBL14656413 | 0.87 | SLC22A12 (0.48) | SLC22A12ARTTRPLA2G7ALDH1A1 | |
| SCHEMBL4809997 | 0.87 | SLC22A12 (0.47) | SLC22A12ARESRRATRPV4ALDH1A1 | |
| SCHEMBL14656131 | 0.87 | SLC22A12 (0.51) | SLC22A12ARESRRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9273054-B2 | Substituted pyrimido[1,6-a]pyrimidines as Lp-PLA2 inhibitors | GLAXO GROUP LIMITED (GB) | 2016-03-01 | — | — | US | disclosed |
| US-9273054-B2 | Substituted pyrimido[1,6-a]pyrimidines as Lp-PLA2 inhibitors | GLAXO GROUP LIMITED (GB) | 2016-03-01 | — | — | US | disclosed |
| US-8975400-B2 | 2,3-dihydroimidazo[1, 2-c] pyrimidin-5(1 H)-one compounds use as LP-PLA2 inhibitors | GLAXO GROUP LIMITED (GB) | 2015-03-10 | — | — | US | disclosed |
| US-8975400-B2 | 2,3-dihydroimidazo[1, 2-c] pyrimidin-5(1 H)-one compounds use as LP-PLA2 inhibitors | GLAXO GROUP LIMITED (GB) | 2015-03-10 | — | — | US | disclosed |
| US-20140179716-A1 | BICYCLIC PYRIMIDONE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2014-06-26 | — | — | US | disclosed |
| US-20140179716-A1 | BICYCLIC PYRIMIDONE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2014-06-26 | — | — | US | disclosed |
| US-20140179715-A1 | 2,3-DIHYDROIMIDAZO[1 ,2-c] PYRIMIDIN-5(1 H)-ONE COMPOUNDS USE AS LP-PLA2 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2014-06-26 | — | — | US | disclosed |
| US-20140179715-A1 | 2,3-DIHYDROIMIDAZO[1 ,2-c] PYRIMIDIN-5(1 H)-ONE COMPOUNDS USE AS LP-PLA2 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2014-06-26 | — | — | US | disclosed |
| EP-2739627-A1 | 2,3-DIHYDROIMIDAZO[1,2-C]PYRIMIDIN-5(1H)-ONE COMPOUNDS USE AS LP-PLA² INHIBITORS | Glaxo Group Limited (GB) | 2014-06-11 | — | — | EP | disclosed |
| US-20130030012-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2013-01-31 | — | — | US | disclosed |
| US-20130030012-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2013-01-31 | — | — | US | disclosed |
| WO-2013013503-A1 | 2,3-DIHYDROIMIDAZO[1,2-C] PYRIMIDIN-5(1H)-ONE COMPOUNDS USE AS LP-PLA2 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-01-31 | — | — | WO | disclosed |
| WO-2013014185-A1 | BICYCLIC PYRIMIDONE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2013-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179715-A1 | 2,3-DIHYDROIMIDAZO[1 ,2-c] PYRIMIDIN-5(1 H)-ONE COMPOUNDS USE AS LP-PLA2 INHIBITORS | PLA2G4A, PLA2G4C, PLA2G4B | SLC22A12 4052/4885AR 3960/4885ESRRA 4578/4885 |
| US-20140179716-A1 | BICYCLIC PYRIMIDONE COMPOUNDS | PLA2G7, PLA2G4A, PLA2G1B | SLC22A12 3061/4885AR 4584/4885ESRRA 4814/4885 |
| US-20130030012-A1 | COMPOUNDS | LPCAT1, PLA2G7, PLAAT2 | SLC22A12 3088/4885AR 4420/4885ESRRA 4156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.